A Functional Role for Prolyl Hydroxylases (PHDs) in Cardiomyopathy

脯氨酰羟化酶 (PHD) 在心肌病中的功能作用

基本信息

  • 批准号:
    8293240
  • 负责人:
  • 金额:
    $ 13.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-30 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal describes a 4 year training program for career development in academic cardiovascular (CV) medicine. The principal investigator has completed clinical and research training in CV medicine at Brigham and Women's Hospital and will embark on a research program designed to provide additional scientific training required for an independent biomedical research career. This program will provide sound principles and expertise for studying the master transcription factor Hypoxia-Inducible Factor-a (HIFa) as it applies to myocyte biology and heart failure. A joint mentorship between Dr. William Kaelin, a Howard Hughes Investigator, Professor of Medicine at Harvard Medical School and a pioneer in cellular signaling in hypoxia, and Dr. Ronglin Liao, associate professor of medicine at Harvard Medical School and an expert in cardiomyocyte biology, has been forged to foster the applicant's scientific and career development. The investigator has established a novel model for spontaneous heart failure in mice deficient in PHD2, a prolyl hydroxylase that regulates the stabilization and activity of HIFa. The specific aims of this proposal are: 1) To determine the functional consequence of PHD2 inactivation in the cardiomycoyte in vivo and ex vivo. 2) To test whether PHD3 partially compensates for PHD2 loss in vivo and specifically in the heart 3) To test the hypothesis that HIFa is necessary and sufficient for the development of cardiomyopathy seen in cardiac- specific PHD2-/- mice. RELEVANCE (See instructions): Heart failure represents an enormous medical and societal burden, affecting over 5 million people in the USA, and its incidence is only increasing with an aging population and prolongation of the lives of cardiac patients. This research aims to understand the fundamental mechanisms of heart failure with the ultimate goal of finding new therapies to prevent and treat this devastating illness. (End of Abstract)
描述(由申请人提供):本提案描述了一个为期4年的学术心血管(CV)医学职业发展培训计划。主要研究者已在布里格姆妇女医院完成了CV医学的临床和研究培训,并将开始一项研究计划,旨在提供独立生物医学研究职业所需的额外科学培训。该计划将为研究主转录因子缺氧诱导因子-a(HIF a)提供良好的原则和专业知识,因为它适用于肌细胞生物学和心力衰竭。霍华德休斯研究员、哈佛医学院医学教授、缺氧中细胞信号传导的先驱William Kaelin博士和哈佛医学院医学副教授、心肌细胞生物学专家Ronglin Liao博士之间的联合导师关系已经建立,以促进申请人的科学和职业发展。研究者已经在PHD 2缺陷的小鼠中建立了一种新型的自发性心力衰竭模型,PHD 2是一种调节HIF a稳定性和活性的脯氨酰羟化酶。该提议的具体目的是:1)确定体内和离体心肌细胞中PHD 2失活的功能后果。2)测试PHD 3是否部分补偿体内并且特别是心脏中的PHD 2损失3)测试HIF a对于心脏特异性PHD 2-/-小鼠中观察到的心肌病的发展是必要和充分的假设。相关性(参见说明):心力衰竭是一个巨大的医疗和社会负担,影响着美国超过500万人,其发病率只会随着人口老龄化和心脏病患者寿命的延长而增加。这项研究旨在了解心力衰竭的基本机制,最终目标是找到预防和治疗这种毁灭性疾病的新疗法。 (End摘要)

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Breast cancer therapies and cardiomyopathy.
  • DOI:
    10.1016/j.mcna.2012.07.008
  • 发表时间:
    2012-09
  • 期刊:
  • 影响因子:
    5.9
  • 作者:
    Groarke, John;Tong, Dan;Khambhati, Jay;Cheng, Susan;Moslehi, Javid
  • 通讯作者:
    Moslehi, Javid
21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.
  • DOI:
    10.1016/j.jacbts.2016.05.008
  • 发表时间:
    2016-08
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Sheng CC;Amiri-Kordestani L;Palmby T;Force T;Hong CC;Wu JC;Croce K;Kim G;Moslehi J
  • 通讯作者:
    Moslehi J
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Javid J Moslehi其他文献

Javid J Moslehi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Javid J Moslehi', 18)}}的其他基金

Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension
VEGF 受体抑制剂相关高血压的新机制和预测因子
  • 批准号:
    10670742
  • 财政年份:
    2022
  • 资助金额:
    $ 13.88万
  • 项目类别:
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension
VEGF 受体抑制剂相关高血压的新机制和预测因子
  • 批准号:
    10554695
  • 财政年份:
    2022
  • 资助金额:
    $ 13.88万
  • 项目类别:
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension
VEGF 受体抑制剂相关高血压的新机制和预测因子
  • 批准号:
    10183300
  • 财政年份:
    2019
  • 资助金额:
    $ 13.88万
  • 项目类别:
A Functional Role for Prolyl Hydroxylases (PHDs) in Cardiomyopathy
脯氨酰羟化酶 (PHD) 在心肌病中的功能作用
  • 批准号:
    8098024
  • 财政年份:
    2009
  • 资助金额:
    $ 13.88万
  • 项目类别:
A Functional Role for Prolyl Hydroxylases (PHDs) in Cardiomyopathy
脯氨酰羟化酶 (PHD) 在心肌病中的功能作用
  • 批准号:
    7923853
  • 财政年份:
    2009
  • 资助金额:
    $ 13.88万
  • 项目类别:
A Functional Role for Prolyl Hydroxylases (PHDs) in Cardiomyopathy
脯氨酰羟化酶 (PHD) 在心肌病中的功能作用
  • 批准号:
    7713621
  • 财政年份:
    2009
  • 资助金额:
    $ 13.88万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 13.88万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 13.88万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.88万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.88万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 13.88万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.88万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 13.88万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 13.88万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 13.88万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.88万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了